SG11201609350XA - Methods for inhibiting necroptosis - Google Patents
Methods for inhibiting necroptosisInfo
- Publication number
- SG11201609350XA SG11201609350XA SG11201609350XA SG11201609350XA SG11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- inhibiting necroptosis
- necroptosis
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014901804A AU2014901804A0 (en) | 2014-05-15 | Methods for inhibiting necroptosis | |
AU2014903569A AU2014903569A0 (en) | 2014-09-08 | Methods for inhibiting necroptosis | |
PCT/AU2015/050246 WO2015172203A1 (en) | 2014-05-15 | 2015-05-15 | Methods for inhibiting necroptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201609350XA true SG11201609350XA (en) | 2016-12-29 |
Family
ID=54479055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609350XA SG11201609350XA (en) | 2014-05-15 | 2015-05-15 | Methods for inhibiting necroptosis |
Country Status (10)
Country | Link |
---|---|
US (1) | US20170114025A1 (en) |
EP (1) | EP3142667A4 (en) |
JP (1) | JP2017521477A (en) |
CN (1) | CN106456632A (en) |
AU (1) | AU2015258781A1 (en) |
BR (1) | BR112016026544A2 (en) |
CA (1) | CA2948544A1 (en) |
RU (1) | RU2016144911A (en) |
SG (1) | SG11201609350XA (en) |
WO (1) | WO2015172203A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110573509B (en) * | 2017-02-28 | 2023-05-26 | 北京生命科学研究所 | MLKL inhibitors |
CN110769853B (en) * | 2017-04-17 | 2022-06-03 | 北京生命科学研究所 | Treatment of male aging |
WO2019246163A1 (en) * | 2018-06-18 | 2019-12-26 | President And Fellows Of Harvard College | Methods of inducing regulated cell death by administering mlkl modulators |
AR115966A1 (en) | 2018-08-17 | 2021-03-17 | Pi Industries Ltd | PHENYLAMIDINE COMPOUNDS AND THEIR USES |
WO2021031893A1 (en) * | 2019-08-21 | 2021-02-25 | National Institute Of Biological Sciences, Beijing | Prostatitis treatment |
WO2021168521A1 (en) * | 2020-02-27 | 2021-09-02 | Anaxis Pharma Pty Ltd | Inhibitors of necroptosis |
EP3906924A1 (en) * | 2020-05-08 | 2021-11-10 | Eberhard Karls Universität Tübingen | Modulation of mixed lineage kinase domain-like protein signaling |
BR112022025732A2 (en) * | 2020-06-19 | 2023-03-07 | Anaxis Pharma Pty Ltd | SULPHONAMIDE COMPOUNDS |
WO2022065962A1 (en) * | 2020-09-28 | 2022-03-31 | 한국화학연구원 | Mlkl binding or degrading compound and pharmaceutical use thereof |
WO2023115149A1 (en) * | 2021-12-22 | 2023-06-29 | Anaxis Pharma Pty Ltd | Bifunctional sulphonamide compounds |
CN117250353B (en) * | 2023-11-16 | 2024-01-16 | 细胞生态海河实验室 | Application of means for regulating and controlling programmed necrosis in preparing kit for diagnosing or delaying aging of blood system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7459455B2 (en) * | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
US20110098288A1 (en) * | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
EP2475648A1 (en) * | 2009-09-11 | 2012-07-18 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
-
2015
- 2015-05-15 SG SG11201609350XA patent/SG11201609350XA/en unknown
- 2015-05-15 WO PCT/AU2015/050246 patent/WO2015172203A1/en active Application Filing
- 2015-05-15 JP JP2017512073A patent/JP2017521477A/en active Pending
- 2015-05-15 US US15/311,020 patent/US20170114025A1/en not_active Abandoned
- 2015-05-15 EP EP15791923.4A patent/EP3142667A4/en not_active Withdrawn
- 2015-05-15 RU RU2016144911A patent/RU2016144911A/en unknown
- 2015-05-15 BR BR112016026544A patent/BR112016026544A2/en not_active Application Discontinuation
- 2015-05-15 CN CN201580025300.8A patent/CN106456632A/en active Pending
- 2015-05-15 AU AU2015258781A patent/AU2015258781A1/en not_active Abandoned
- 2015-05-15 CA CA2948544A patent/CA2948544A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170114025A1 (en) | 2017-04-27 |
CN106456632A (en) | 2017-02-22 |
BR112016026544A2 (en) | 2017-12-12 |
WO2015172203A1 (en) | 2015-11-19 |
RU2016144911A (en) | 2018-06-18 |
EP3142667A4 (en) | 2017-12-20 |
EP3142667A1 (en) | 2017-03-22 |
AU2015258781A1 (en) | 2016-11-24 |
JP2017521477A (en) | 2017-08-03 |
CA2948544A1 (en) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | Smyd inhibitors | |
IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
GB201406151D0 (en) | Method | |
GB201409558D0 (en) | Method | |
GB201406155D0 (en) | Method | |
HK1226398A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
GB201408119D0 (en) | Method | |
IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
GB201413086D0 (en) | Methods | |
SG11201609350XA (en) | Methods for inhibiting necroptosis | |
GB201403470D0 (en) | Method | |
GB201410022D0 (en) | Method | |
GB201420832D0 (en) | Location method | |
GB201410101D0 (en) | Method | |
GB201408745D0 (en) | Methods | |
GB201409128D0 (en) | Method | |
GB201409234D0 (en) | Method | |
GB201409101D0 (en) | Method | |
GB201415685D0 (en) | Methods | |
GB201408649D0 (en) | Method | |
GB201418154D0 (en) | Inhibitors | |
AU2014903569A0 (en) | Methods for inhibiting necroptosis | |
GB201414122D0 (en) | Methods | |
AU2014901804A0 (en) | Methods for inhibiting necroptosis | |
GB201410462D0 (en) | Method |